 | | Vol. 7.11 – 4 April, 2022 |
| |
|
|
| Investigators generated chemically induced cardiovascular progenitor cells self-renewed long-term in fully chemically defined and xeno-free conditions, with faithful preservation of the cardiovascular progenitor cell phenotype and of cardiovascular differentiation capacity in vitro and in vivo.
[Nature Biomedical Engineering] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers described a new method of constructing a vascular network in vivo that allowed for the construction of thick human myocardial tissue from multi-layered cell sheets.
[NPJ Regenerative Medicine] |
|
|
|
| Scientists performed molecular dynamic simulations to determine the effect of missense variant rs2229774 on retinoic acid receptor gamma (RARG) structure and then validated these predictions using CRISPR-Cas9-genome-edited, induced pluripotent stem cell-derived cardiomyocytes.
[Stem Cell Reports] |
|
|
|
| To enhance the maturation of human embryonic stem cell-derived cardiomyocytes (hESC-CMs), the authors identified a natural steroidal alkaloid, tomatidine, as a new substance that stimulated the maturation of hESC-CMs.
[Experimental and Molecular Medicine] |
|
|
|
| Investigators explored the antipyroptotic effects of long noncoding RNA (lncRNA) FGF9-associated factor (FAF) in acute myocardial infarction.
[Journal of Cellular and Molecular Medicine] |
| |
|
|
| Researchers induced endoplasmic reticulum (ER) stress and lipotoxicity in myotubes and observed ER stress-inducing lipid cell non-autonomous signals.
[Nature Communications] |
|
|
|
| Scientists reported that Sirt6, an anti-aging histone deacetylase, was critical in regulating myofiber configuration toward oxidative type and that Sirt6 activator could be an exercise mimetic.
[Nature Communications] |
|
|
|
| The authors examined the involvement of insufficient Parkin-mediated mitophagy, a mitochondrion-selective autophagy, in the mechanisms by which dysfunctional mitochondria accumulated with excessive reactive oxygen species production in the development of chronic obstructive pulmonary disease-related sarcopenia.
[Journal of Cachexia Sarcopenia and Muscle] |
|
|
|
| Researchers recapitulated the time course of fetal skeletal muscle development in vitro and explored the dynamic changes of chromatin accessibility and gene expression during bovine myoblasts proliferation and differentiation.
[Cell Proliferation] |
| |
|
|
| The authors investigated the mechanism of bone marrow mesenchymal stem cell-derived exosome using high phosphate stimulated human aortic smooth muscle cells and nephrectomy rat models.
[Cell Death & Disease] |
|
|
|
| Irisin effectively inhibited β-glycerophosphate-induced calcium deposition in vascular smooth muscle cells (VSMCs) in vitro and in mice aortic rings ex vivo. Overexpression of NLR family pyrin domain containing 3 (Nlrp3) attenuated the suppressive effect of Irisin on VSMC calcification.
[Cell Death & Disease] |
|
|
|
| Scientists unraveled the substantial contribution of miRNAs in regulating the smooth muscle cell (SMC) transcriptome and identified the miR-200 cluster as a pro-quiescence mechanism and a potential inhibitor of vascular restenosis.
[iScience] |
|
|
|
|
Researchers investigated whether local delivery of adeno-associated viral (AAV) vectors expressing oxidation-resistant wild type apolipoprotein A1 (apoA1) preserved apoA1 functionality.
[Scientific Reports] |
|  | |
|
|
| The authors discuss mitochondrial-derived vesicle generation and release as a mitophagy-complementing route for the maintenance of mitochondrial homeostasis in skeletal myocytes.
[Seminars in Cell & Developmental Biology] |
|
|
|
| Early vascular aging (EVA) is distinct from chronological aging, and research is ongoing to identify a definitive molecular signature of EVA to facilitate the discovery of new clinical tests for early detection of EVA and identify therapeutic targets to prevent EVA in smooth muscle cells.
[Biochimica Et Biophysica Acta-Molecular Basis of Disease] |
|
|
|
|
| Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. announced the initiation of a rolling new drug application (NDA) submission to the US FDA for vamorolone for the treatment of Duchenne muscular dystrophy.
[Santhera Pharmaceuticals] |
|
|
|
|
| June 15 – 18, 2022
San Francisco, California, United States |
|
|
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | University of California, San Diego – La Jolla, California, United States |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
